DEEP VEIN THROMBOSIS and Lisinopril

PatientsVille

Find and Compare Side Effects

DEEP VEIN THROMBOSIS Symptoms and Causes

Deepveinthrombosis, or DVT, is a blood clot that forms in a veindeep in the body. Most deepvein clots occur in the lower leg or thigh. If the vein swells, the condition is called thrombophlebitis. A deepveinthrombosis can break loose and cause a serious problem in the lung, called a pulmonary embolism.

Sitting still for a long time can make you more likely to get a DVT. Some medicines and disorders that increase your risk for blood clots can also lead to DVTs. Common symptoms are

Warmth and tenderness over the vein

Pain or swelling in the part of the body affected

Skin redness

Treatment includes medicines to ease pain and inflammation, break up clots and keep new clots from forming. Keeping the affected area raised and applying moist heat can also help. If you are taking a long car or plane trip, take a break, walk or stretch your legs and drink plenty of liquids.

DEEP VEIN THROMBOSIS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

Reduction in incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment as measured by preservation of LVEF; Comparison of the LVEF of each treatment group with the placebo arm; Number of trastuzumab courses completed without interruption; Quality-of-life changes as assessed by EORTC-QLQ-C30 questionnaire at baseline and at the end of treatment; Long-term effects of study drugs as assessed at 18 and 24 months (or 6 and 12 months after completion of trastuzumab therapy)

Incidence of grade 3 or higher hypotension, acute kidney injury, allergic reaction, or anaphylaxis, as measured using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0; Incidence of adverse events as measured using the NCI CTCAE version 4.0; Quality of life, assessed using lung cancer symptom scale (LCSS), Functional Assessment of Cancer Treatment Lung Cancer (FACT-L), and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer (EORTC-QLQ-LC13); Incidence of acute respiratory distress (dyspnea), measured using the maximum score, at any time, of the shortness of breath question on the LCSS; Patient-level symptoms as measured using the Symptom Experience Questionnaire (SEQ)

Parathyroid hormone, before and after, ACE inhibitor administration; Serum and urinary aldosterone measurements before and after ACE inhibitor use; Serum calcium before and after ACE inhibitor administration

To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular and renal risk assessment.; To evaluate the influence of circadian time of treatment in BP control of hypertensive patients.; To evaluate the prevalence of an altered (non-dipper) BP profile in patients with resistant hypertension as a function of the circadian time of treatment.; To evaluate the influence of diabetes and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.; To evaluate the influence of age and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.; To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of white-coat hypertension.; To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of masked hypertension.; To evaluate, for all previous objectives, potential differences between men and women.; To evaluate the impact of changes in ambulatory BP in cardiovascular, cerebrovascular and renal risk assessment.

There may be a statistical correlation between eGFR(estimated glomerular function) and PWV (pulse wave velocity) in patients with CKD, the addition of an ACE inhibitor will decrease PWV in all groups, but to a greater extent in patients wil CKD.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.